Compare GSK plc (GSK) vs KeyCorp (KEY) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

KeyCorp (KEY) trades at $23.30, up 0.34% with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and net income margin improving to 26.05%. Recent corporate developments include a $0.21 dividend declaration and a new $3 billion buyback program representing 12% of market cap, signaling management confidence in capital returns.

With 61% analyst buy ratings and a $29.32 consensus price target suggesting 26% upside, KEY presents a compelling value opportunity. However, investors should monitor the bank's ability to sustain revenue growth above $7 billion and navigate potential interest rate volatility that could impact net interest income margins.